The principal goals of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) are prevention of stent thrombosis and, in those treated for acute coronary …

Dual antiplatelet therapy (DAPT) has been paramount in preventing thrombosis following
percutaneous coronary intervention for nearly 3 decades. However, over the years, DAPT …

In 1998, Leon et al.(1) demonstrated the superiority of dual antiplatelet therapy (DAPT) over
alternative antithrombotic regimens in the prevention of stent thrombosis among patients …

Dual antiplatelet therapy (DAPT) is an evidence-based, guideline-recommended, standard-
of-care treatment after percutaneous coronary intervention (PCI)(1). Nevertheless, the …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the treatment
of choice for the prevention of thrombotic events after percutaneous coronary intervention …

Antiplatelet therapy is the cornerstone of secondary cardiovascular prevention after
percutaneous coronary intervention (PCI). 1 Improvements in drug-eluting stent (DES) …

Opinion statement While dual antiplatelet therapy (DAPT), after percutaneous coronary
intervention (PCI) has demonstrated benefit for two important cardiovascular indications, 1) …

Heart Association guidelines on duration of dualantiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) give a class I …

Dual-antiplatelet therapy (DAPT) is recommended after percutaneous coronary intervention
(PCI) for patients presenting with chronic coronary syndrome as well as acute coronary …

Platelets initiate the formation of a thrombus at the site of an arterial injury, and the clotting
cascade is activated as the thrombus matures. After coronary stent placement, dual …